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Summary
The WHO recommends screening of Latin American mi-
grants for Chagas disease to reduce morbidity and mortal-
ity and increase the likelihood of eradicating the disease.
The objective was to assess the feasibility and accept-
ability of a screening strategy in one Swiss canton. From
February 2011 to September 2012, people attending six
healthcare centres of different types were offered a rapid
diagnostic test if they or their mother were of Latin Amer-
ican origin (or, at the blood donation centre, if they had
travelled for ≥1 year in Latin America). In addition, testing
was offered during events where Latin Americans gath-
ered. In total, 1,010 people were tested, mainly originating
from Brazil (24%), Ecuador (13%) and Chile (10%). 54%
were born in Latin America, 15% had a Latin American
mother, and 29% were travellers. The prevalence of Cha-
gas disease was 2.3% among migrants (15.5% in the
community testing) and 0% among travellers. The preva-
lence was 18.0%, 0.8%, 0.5% and 0% among Bolivians,
Ecuadorians, Brazilians and other countries respectively.
Predictors for Chagas disease were: born in Latin America
(OR = infinite, p <0.001), Bolivian origin (OR = 95, 95%
CI: 19–482, p <0.001), being tested in the community (OR
= 56, 95% CI: 14–218, p <0.001), and age >35 years OR
= 3.4, 95% CI: 1.1–10.5, p = 0.03). The prevalence of
Chagas disease was much higher in people attending so-
cial events than healthcare centres, suggesting that obser-
vations based only on health facility data underestimate
the real prevalence of Chagas disease. Screening in the
community was well accepted and should be promoted to
reach the population at highest risk.
Keywords: Chagas disease, migrants, screening, non-en-
demic country, rapid diagnostic test, blood donors, prima-
ry care, community
Introduction
Chagas disease is caused by Trypanosoma cruzi, a tropical
protozoan parasite transmitted by the blood-sucking bug
Triatoma. It affects around 8 million people worldwide and
is no longer restricted to Latin America. Migration and
travel have caused the disease to spread out of the conti-
nent and reach most countries in the world. This phenom-
enon has been observed particularly in populations able to
transmit the disease in the absence of the vector, such as in
pregnant women through vertical transmission [1–4] and
blood and organ donors [5–10]. This situation has led the
World Health Organization (WHO) to recommend screen-
ing migrants of Latin American origin living in non-en-
demic countries for Chagas disease [11, 12], both to reduce
morbidity and mortality, and to work towards eradicating
the disease globally. Providing treatment to patients with
Chagas disease would not only reduce their risk of devel-
oping potentially severe cardiac or intestinal impairments,
but would also help to stop transmission in women of
childbearing age and through blood transfusions or organ
transplants. However, the best screening strategy is not yet
known and might not be the same for all settings. Test-
ing of sick patients attending primary healthcare centres
has existed for many years in some non-endemic coun-
tries, but the systematic screening of asymptomatic people
has been introduced more recently. The latter now exists in
several cities in Spain, such as Barcelona [13–15], Asturias
[16], Elche [17] and Madrid [18], as well as in Italy [19],
France [20] and Canada [21]. These studies have enabled
us to know the true prevalence of the disease among Latin
American migrants, which is essential in order to design an
efficient screening strategy. In Geneva, Switzerland, peo-
ple attending a primary healthcare facility specifically for
migrants have been screened [4], revealing that 12.8% of
people tested were positive. This high prevalence and the
large Latin American population living in Switzerland (es-
timated to be around 80,000 people [22–24]), highlight the
importance of investigating the situation in the nearby can-
ton of Vaud, where testing for Chagas disease had never
been offered and the prevalence is thus totally unknown.
In addition to the prevalence of the disease, knowledge of
the positive predictors for Chagas disease is important to
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better target screening for the highest risk population. The
few studies which have investigated predictors in asymp-
tomatic migrants have found that Bolivian origin [4], hav-
ing heard about the disease, knowing someone with Cha-
gas disease, and having lived in adobe houses and rural
areas [13] are significantly associated with having the dis-
ease.
Another important element in the design of an effective
screening strategy is the type of diagnostic test to be used.
Rapid diagnostic tests with excellent performance [25, 26]
are available for Chagas and are ideal in the context of a
mobile population because they allow immediate results. It
is also essential to understand the acceptability of and bar-
riers to screening in the migrant Latin American popula-
tion to have a feasible and durable strategy.
This study aims to assess the feasibility and acceptability
of a systematic screening strategy for Chagas disease in
the canton of Vaud. It also aims to estimate the number of
people needed to test, according to demographic and clini-
cal characteristics, for screening to focus on the population
most at risk in the future.
Materials and methods
Population and setting
The study took place in six healthcare centres located in
Lausanne and the surrounding area. The inclusion criteria
were being born (or having spent a considerable part of
infancy) in Latin America or having a mother who was
born in Latin America (excluding the Caribbean). At the
Department of Ambulatory Care and Community Medi-
cine (DACCM), which serves as an outpatient clinic for the
University Hospital of Lausanne, the clinician in charge
offered a rapid diagnostic test for 20 Swiss francs (22
USD) during routine emergency consultations. At the Point
d’Eau (PDE), an urban, low-level healthcare centre attend-
ed mainly by undocumented immigrants, the three nurse
practitioners offered a rapid test during the usual consul-
tation for 3 Swiss francs. At the maternity hospital, Latin
American women attending the obstetric clinic were of-
fered the diagnostic test for 60 Swiss Francs (66 USD).
The test was also offered during consultations at two fam-
ily planning centres (FPC), which provide sexual coun-
selling and related activities, for the price of 22 Swiss
francs (24 USD). Systematic screening was implemented
at the blood donation centre (BDC), where an additional
inclusion criterion was used: having travelled in Latin
America for more than one year. Finally, screening was of-
fered free of charge during events (such as cultural celebra-
tions) where people of Latin American origin, Bolivians in
particular, gathered (see fig. 1 below).
Study design
From February 2011 to September 2012, Latin Americans
attending the six healthcare centres mentioned above were
offered screening for Chagas disease. Screening was first
offered to patients attending the DACCM and the PDE.
The screening was extended to the two FPC in November
2011 and to pregnant women attending the maternity hos-
pital in January 2012. At the blood donation centre, people
were tested from the beginning of the study. In May 2012,
screening in the community was proposed by a team com-
posed of a Bolivian pharmacist working as cultural media-
tor, a medical doctor specialising in tropical diseases, a Bo-
livian medical doctor and a master’s student in medicine
working on the topic. Latin American associative organi-
sations were contacted to assist in choosing events which
attracted sufficient numbers of people and to help dis-
seminate the information. A leaflet and poster explaining
the transmission, symptoms, clinical course, screening and
treatment of Chagas disease in French, Spanish and Por-
tuguese, were developed based on a Spanish leaflet from
the “Hospital Universitario Ramón y Cajal” of Madrid.
These educational materials helped to spread information
about the availability of screening at the different health-
care centres, as well as the management and treatment of
positive cases.
A rapid diagnostic test (Chagas Stat-Pak, Chembio, USA)
was used in all settings except at the blood donation centre,
where a serology test was used. At the maternity hospital,
the rapid test was performed at the central laboratory at
the same time as the other screening tests required during
pregnancy. An internal quality control test was performed
on each new batch of rapid diagnostic tests. When the test
was positive, patients were offered an appointment at the
Tropical Diseases Unit of the DACCM for confirmation of
the diagnosis by conventional serology (BioElisa Chagas,
Biokit®), and management and treatment of Chagas dis-
ease.
Data collection and analysis
Age, sex, country of origin or travel, eligibility criteria
and test results (the main outcome measure) were collected
prospectively. At the DACCM, the PDE and the maternity
hospital, nine symptoms and signs (dyspnoea, palpitations,
chest pain, dysphagia, odynophagia, constipation, signs or
symptoms of cardiac insufficiency, abnormal cardiac
sounds and intestinal obstruction) known to be predictive
of symptomatic Chagas disease [27] were assessed by the
clinician in charge. Data were collected prospectively and
anonymously, and entered into an Excel database which
was then analysed in Stata version 10.1. Simple propor-
tions and crude odds ratios (a simple stratification was
used to adjust for Bolivian origin) were calculated, as were
95% confidence intervals (95% CI) using the exact test and
p-values (two-sided) using Pearson χ2 statistics.
Ethical considerations
The study, including the use of verbal consent, was ap-
proved by the ‘Commission cantonale d’éthique de la
recherche sur l’être humain’, Lausanne, Switzerland. Ver-
bal consent testified by the written signature of the health
worker in charge of the diagnostic testing was obtained for
each participant prospectively. Written consent could not
be obtained because most of the participants had an ille-
gal status in Switzerland and were afraid that writing their
name could lead to denunciation.
Results
Population tested
In total, 1010 adults were tested for Chagas disease: 107
(11%) at the DACCM, 83 (8%) at the PDE, 32 (3%) at
the two FPC, 11 (1%) at the maternity hospital, 693 (69%)
at the BDC and 84 (8%) in the community. 593 (59%)
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were women (0.2% unknown). The median age was 34
years (IQR 25–46, range 7–76). The most frequent coun-
tries of origin (or travel) were: 238 (24%) Brazil, 133
(13%) Ecuador, 100 (10%) Chile, 90 (9%) Colombia, 89
(9%) Peru and 78 (8%) Bolivia. Table 1 details the dis-
tribution of country of origin for each testing centre. 546
(54%) were born in Latin America, 152 (15%) had a Latin
American mother and 291 (29%) were travellers (2% un-
known). The travellers had a mean duration of stay in Latin
America of four years (IQR 1.2-10.0, range 0.25-34). Sex,
median age, screening criteria and positive results are pre-
sented by country in table 2 and figure 1. Among the 231
patients who were asked about symptoms and signs pre-
dictive of Chagas disease, 28 (12%) presented with one or
more symptoms/signs, the most frequent being dyspnoea
and precordialgia, which were found in eight participants
each, and constipation, found in five people.
Positive cases for Chagas disease
The overall prevalence was 1.6% (16/1010, 95% CI:
0.9–2.6%) and therefore the number needed to test was 63.
Among migrants (excluding travellers), the prevalence was
2.3% (16/698, 95% CI: 1.3–3.7%). None of the travellers
who presented at the BDC were affected. The prevalence
in the community was 15.5% (13/84, 95% CI: 8.5–25.0%),
at the DACCM it was 2.8% (3/107, 95% CI: 0.6–8.0%),
and at the other testing sites it was 0% (fig. 2). The preva-
lence was 18.0% (14/78, 95% CI: 10.2–28.3%) among Bo-
livians, 0.4% (1/238, 95% CI: 0–2.3%) among Brazilians,
0.8% (1/133, 95% CI: 0–4.1%) among Ecuadorans and 0%
among persons originating from other countries. The me-
dian age of the 16 positive Chagas cases was 45 years
(IQR 36–52, range 30–56), compared to a median age of
34 years for negative persons (p = 0.03). Interestingly, on-
ly 1 of the 42 (2%) Bolivians tested at the healthcare clin-
ics was positive, while 13 of the 36 (36%) Bolivians test-
ed in the community were positive (table 2). All positive
cases were born in Latin America. The three positive cases
who were asked about the symptoms and signs predictive
of Chagas disease all had at least one of them.
Figure 1: Screening places for Chagas disease. The Depart-
ment of Ambulatory Care and Community Medicine (DACCM)
serves as an outpatient clinic for the University Hospital of Lau-
sanne; the Point d’Eau (PDE) is an urban, low-level healthcare
centre attended mainly by undocumented immigrants; the family
planning centres (FPC) provide sexual counselling and related ac-
tivities.
Table 1: Number and characteristics of persons tested by country and by screening location.
Screening loca-
tion
Total
Community Blood donation
centre
Maternity hospital Department of
ambulatory care
and community
medicine
Point d’Eau Family planning
centres
Female (n, %) 60 (71%) 352 (51%) 11 (100%) 69 (64%) 71 (86%) 30 (94%) 593 (59%)
Age in years (median,
IQR)
41 (32–49) 33 (24–46) 31 (26–35) 33 (25–41) 42 (32–51) 31 (28–39) 34 (25–46)
Country n n (%)
Brazil 0 178 3 32 (1 pos) 19 6 238 (24%)
Ecuador 25 26 3 34 (1 pos) 30 15 133 (13%)
Chile 4 82 2 7 5 0 100 (10%)
Colombia 4 65 0 12 3 6 90 (9%)
Peru 14 59 2 6 8 6 89 (9%)
Bolivia 36 (13 pos) 20 1 10 (1 pos) 7 4 78 (8%)
Mexico 0 49 0 1 0 1 51 (5%)
Argentina 0 44 0 2 0 0 46 (5%)
Venezuela 1 38 0 2 1 0 42 (4%)
Uruguay 0 16 0 0 1 0 17 (2%)
Guyana 0 12 0 0 0 0 12 (1%)
Guatemala 0 10 0 0 2 0 12 (1%)
Nicaragua 0 9 0 0 0 0 9 (1%)
Costa Rica 0 8 0 0 0 0 8 (1%)
Paraguay 0 1 0 0 7 0 8 (1%)
El Salvador 0 8 0 0 0 0 8 (1%)
Honduras 0 6 0 0 0 0 6 (1%)
Panama 0 4 0 0 0 0 4 (0%)
Not recorded 0 58 0 1 0 0 59 (6%)
Total n (%) 84 (8%)
(15% pos)
693 (69%) 11 (1%) 107 (11%)
(3% pos)
83 (8%) 32 (3%) 1010 (100%)
(1.6% pos)
IQR = interquartile range Positive (pos) Chagas cases are shown in italics.
Original article Swiss Med Wkly. 2019;149:w20050
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 7
Figure 2: Number of persons tested for Chagas disease by country and by screening place. Groups with positive cases are pointed with
arrows. Care structures include the Department of Ambulatory Care and Community Medicine (DACCM), the Point d’Eau (PDE), the family
planning centres (FPC) and the maternity hospital.
Predictors for positivity
Regarding the predictors of positivity (table 3), being born
in Latin America (n = 546) was the strongest factor (OR
= infinite, p <0.001), followed by Bolivian origin (n = 78,
OR = 95, 95% CI: 19-484, p <0.001) and being tested
in the community (n = 84, OR = 56, 95% CI: 14–219, p
<0.001). The latter factor remained significant even after
adjusting for Bolivian origin (OR = 23, 95% CI: 2–243, p
<0.001). Symptoms of Chagas disease were significantly
associated with positivity, although the number of people
for whom the information was available was very small.
Finally, age >35 years (n = 478, OR = 3.4, 95% CI:
1.1–10.5, p = 0.03) was predictive of Chagas disease, while
sex was not significant (p = 0.76).
Discussion
A prevalence of 2.3% was found for Chagas disease in
Latin American migrants living in the canton of Vaud,
Switzerland. This rate is similar to that found in migrants
attending a healthcare centre in Barcelona over the past
14 years (2.9%) [13]. It is, however, lower than the rates
found in other European cities such as Elche (6.5%) [17],
Madrid (15.9%) [18] and Paris (20.1%) [20]. In Italy, sys-
tematic screening found an overall prevalence (including
travellers, expatriates, adopted children, blood donors and
HIV positive patients) of 4.2% [19], and a prevalence of
Table 2: Number of persons tested, proportion of women, distribution of screening criteria, median age and number of positive cases, by country.
Country Number of persons tested
n (%)
Proportion of women
%
Screening criteria
B/M/T, %*
Age in years
median (IQR)
Number of positive cases
n (%)
Brazil 238 (24%) 59% 56/17/26 35 (25-47) 1 (0.4%)
Ecuador 133 (13%) 63% 89/4/7 35 (29-42) 1 (0.8%)
Chile 100 (10%) 56% 53/23/22 32 (24-49) 0
Colombia 90 (9%) 66% 59/11/29 32 (24-44) 0
Peru 89 (9%) 58% 53/20/25 35 (24-48) 0
Bolivia 78 (8%) 69% 78/5/17 36 (29-48) 14 (17.9%)
Mexico 51 (5%) 61% 24/14/63 27 (22-47) 0
Argentina 46 (5%) 46% 41/24/33 32 (22-47) 0
Venezuela 42 (4%) 38% 43/10/48 44 (33-52) 0
Uruguay 17 (2%) 47% 35/35/29 33 (27-48) 0
Guatemala 12 (1%) 58% 33/8/58 33 (28-40) 0
Guyana 12 (1%) 67% 8/25/67 32 (20-55) 0
Nicaragua 9 (1%) 33% 22/0/78 37 (33-53) 0
Costa Rica 8 (1%) 63% 25/25/50 28 (26-36) 0
Paraguay 8 (1%) 88% 88/0/13 35 (26-41) 0
El Salvador 8 (1%) 63% 38/50/13 22 (20-24) 0
Honduras 6 (1%) 50% 17/33/50 33 (21-46) 0
Panama 4 (0.4%) 75% 25/25/50 45 (32-56) 0
Not recorded 59 (6%) 53% 8/19/56 37 (26-52) 0
Total n (%) 1,010 (100%) 59% 54/15/29 34 (25-46) 16 (1.6%)
IQR = interquartile range B: born in Latin America; M: born to a Latin American mother; T: travel in Latin America * The sum of the three percentages does not always reach 100%
due to missing data.
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Figure 3: Prevalence of Chagas disease found in several studies in non-endemic countries. Studies from Paris, France (21), Madrid,
Spain (19), Geneva, Switzerland (10), Italy (20), Elche, Spain (18), Barcelona, Spain (14-16) and Canada (22). Migrants include people born
in Latin America or born from a Latin American mother.
11.3% among migrants. Only Canada found a lower preva-
lence (1.0%) among refugees [21] (fig. 3). The prevalence
of Chagas disease in our study was much higher in people
attending social events than healthcare centres. This sug-
gests that observations based mainly or exclusively on
healthcare facility data tend to underestimate the true
prevalence of Chagas disease. This testing at social events
could be performed using rapid, point-of-care diagnostic
tests, as few people would be missed due to the high sensi-
tivity of the test (in our study only 0.5 people would have
been falsely negative if the test had 96% sensitivity).
Prevalence according to country of origin
In Geneva, the canton to the east of Vaud, 12.8% of the
1,012 Latin American migrants screened were positive for
Chagas disease [7]. This high prevalence compared to our
study can probably be explained mainly by the high pro-
portion of Bolivians: 48% in Geneva compared to 8% in
Vaud. In support of previous studies, we found that the
majority of affected people originated from Bolivia. The
17.9% prevalence among Bolivians (or 21.5% if we ex-
clude blood donors) is close to that documented in other
studies: Barcelona (16.5%), Madrid (20.9%), Paris
(25.0%) and Geneva (26.2%). Excluding the BDC, where
testing is compulsory, the number needed to test was low
for Bolivians - only four people need to be tested to find a
positive case – but high for migrants originating from other
countries (130). Special attention should therefore be paid
to Bolivians when designing a strategy.
Prevalence according to place of screening
In addition to the country of origin, the high variation in
prevalence between studies can be explained by the dif-
ferent populations screened and the different screening lo-
cations. In our study, the prevalence was much higher in
people tested in the community than at the healthcare clin-
ics, regardless of their country of origin. A possible ex-
planation is that people tested in the community were of
lower social status and thus originating from the rural re-
gions harbouring the highest levels of endemicity of Cha-
gas disease. Indeed, people without a resident permit tend
to avoid contact with the health system as much as possi-
ble, even though the low-level health facility in Lausanne
targets precisely this population, and even though there is
a system in place in the other healthcare facilities for mi-
grants to improve their attendance.
Prevalence in specific populations
None of the 11 pregnant women (of whom only one origi-
nated from Bolivia) screened at the maternity hospital were
positive. In other studies, the prevalence among pregnant
women was 1.3% in Elche [1], 1.4% in Italy [19], 9.7%
in Geneva [4], 3.4% in Barcelona [2] and 4.7% in Valen-
cia [3]. In this study, only a very small proportion (11%)
of the pregnant Latin American women attending the ma-
ternity hospital were tested, and none were positive. Since
the end of the study, the testing rate has improved, how-
ever, and several pregnant women have tested positive in
Vaud. There were also no positive cases detected at the
BDC. In the literature, the prevalence at BDCs varies be-
tween 0% in Porto and Italy [10, 19], 0.003% in France [6],
0.007% in United States [8] and 0.6% in Catalonia [5]. In
Table 3: Predictors of being positive for Chagas disease.
Predictor Total cases
n/N (%)
Positive cases
n/N (%)
Negative cases
n/N (%)
Crude OR
(95% CI)
p-value
Born in Latin America 546/992 (55%) 16/16 (100%) 530/976 (54%) ∞ <0.001
Symptoms of Chagas disease 28/233 (12%) 3/3 (100%) 25/230 (11%) ∞ <0.001
Bolivian origin 78/951 (8%) 14/16 (88%) 64/935 (7%) 95 (19-484) <0.001
Tested in the community 84/1010 (8%) 13/16 (81%) 71/994 (7%) 56 (14-219) <0.001
Tested in the community (when being Boli-
vian)
36/78 (46%) 13/14 (93%) 23/64 (36%) 23 (2-243) <0.001
Age >35 years 478/1006 (48%) 12/16 (75%) 466/990 (47%) 3.4 (1.1-10.5) 0.03
Female sex 593/1008 (59%) 10/16 (63%) 583/992 (59%) 1.2 (0.4 -3.2) 0.76
Original article Swiss Med Wkly. 2019;149:w20050
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 7
Catalonia, donors who have stayed in an endemic country
for more than one month are screened, while in France and
the United States, travellers with a stay of any duration are
screened.
Clinical predictors
Although clinical features could only be evaluated in the
context of medical consultations (and not in counselling
sessions), having symptoms or signs predictive of chronic
Chagas disease was frequent among positive cases (this
evaluation was performed by the physician prior to know-
ing the test result). This might be because transmission
of Chagas has decreased substantially during the past 20
years, meaning that most cases were infected a long time
ago and are therefore more likely to be at the symptomatic
stage of the disease. This hypothesis is corroborated by
the fact that older age was a predictor of positivity in our
study, as well as in a study in Geneva [7]. These symp-
toms and signs were not the reason for the consultation
and would not necessarily have been assessed by the clin-
ician in charge if not required by the study. Theoretically,
to decrease the overall number of people needed to test, the
presence of one of these clinical features could be used as a
screening criterion in populations with a very low pre-test
probability, such as non-Bolivian Latin Americans. How-
ever, a screening strategy also aims to detect people dur-
ing the asymptomatic phase, when treatment has the high-
est potential impact. Moreover, a medical examination is
not pragmatic outside of formal healthcare facilities.
Screening at community level
When the difficulty of reaching those at risk through a
healthcare facility became apparent, direct screening in the
community was offered, targeting particularly people of
Bolivian origin. However, attendance at Latin American
social events requires strong commitment from health
workers, as these often take place outside of normal work-
ing hours. Moreover, it was not always possible to offer
screening for Chagas disease during such events, as or-
ganisers were sometimes afraid that this activity could im-
pact on the celebration. In contrast, we observed that even
when organisers were sceptical, participants at the celebra-
tion were pleased to have the opportunity to become more
informed and, in particular, to be directly screened. The
cultural mediator was a key person in the process of ap-
proaching and convincing the community leaders of the
importance of testing for Chagas disease. We reached the
conclusion that due to the availability of rapid diagnostic
tests for Chagas disease, testing at a community level is
feasible, effective and well accepted by the community.
Feasibility of the screening strategy
The proportion of participants who consented to be tested
was high in all places, except at the maternity hospital. At
the latter, nurses highlighted that patients were declining
the test because of the high price of the test. Indeed, Cha-
gas is not currently part of the screening tests recommend-
ed by the Swiss Society of Gynaecology and Obstetrics
and thus is not reimbursed by healthcare insurance. At the
other facilities, where the price of the test was much low-
er, the uptake on the screening strategy depended mainly
on the method used by the facility to identify Latin Amer-
icans. At the outpatient clinic, for example, the reception-
ist added a reminder for clinicians on the patient’s medical
file if they originated from Latin America, encouraging
a high uptake. In health facilities where the clinician in
charge had to remember to offer the test, the uptake was
much lower, especially when the reason for attendance had
nothing to do with Chagas disease. An unexpected diffi-
culty encountered was convincing people who had test-
ed positive to seek treatment. They reported a number of
fears, including i) being denounced to legal authorities (as
the vast majority of positive cases were undocumented mi-
grants) despite the assurance of total separation between
health and security services in Switzerland, ii) losing their
jobs due to non-attendance relating to the numerous med-
ical consultations, iii) earning less money (as their salary
is often hour-based), and iv) experiencing adverse drug re-
actions (ADRs) from the medication used to treat Chagas
disease. In 2008 in Geneva, nifurtimox was used to treat
Chagas disease, and rumours about serious ADRs spread
in the community. These fears highlight the importance of
an active presence in the community. Providing informa-
tion through leaflets and posters, as we did, is important
but evidently not sufficient to tackle these specific prob-
lems. Possible options to improve confidence in healthcare
could be to create an association of people affected by Cha-
gas disease or to form an expert patient group.
Conclusion
As migration from Latin America to Switzerland is in-
creasing, it is time an efficient strategy for the systematic
screening and treatment of Chagas disease was set up to
stop transmission in non-endemic countries and to de-
crease morbidity. According to our findings, which are
supported by those of other studies, the Bolivian popula-
tion in particular should be targeted. For people originat-
ing from other Latin American countries, where the preva-
lence is much lower, adding criteria that are predictive of
Chagas disease could be a good method to reduce the num-
ber who need testing. Further research on the most effi-
cient combination of criteria for screening is needed, with
the consideration that the profile of the migrant population
may change rapidly, and screening strategies will have to
be adapted accordingly. Screening for Chagas disease di-
rectly in the community, where the positivity rate is much
higher, rather than only at healthcare facilities, is essen-
tial, and allows problems arising from misinformation and
(sometimes justified) fears to be tackled. The warm wel-
come from the Latin American community when screening
was offered to them in a more convenient way, and their
realisation that this neglected and serious disease could be
appropriately managed, should strengthen the willingness
of non-endemic countries to continue to work actively to
achieve the WHO goal of eradicating Chagas disease glob-
ally.
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